(RTTNews) - AstraZeneca and Amgen's Tezspire or tezepelumab has been recommended for approval in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps. The CHMP of the European Medicines Agency based its positive opinion on results from the WAYPOINT Phase III trial.
Regulatory applications are currently under review in the US, China, Japan and several other countries based on the WAYPOINT trial. Tezspire is approved for the treatment of severe asthma in the US, EU, Japan and more than 60 countries.
For More Such Health News, visit rttnews.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
